PT Brigit Biofarmaka Teknologi Tbk
IIDX:OBAT246.00
IDR
+6.00
(+2.50%)
ISIN
ID1000208705
Return %
Stock
S&P 500
1Y
-52.69
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Producer manufacturing
- Industry
- Industrial conglomerates
- Address
- Sukoharjo Indonesia
- IPO Date
- Jan 9, 2025
- Website
- brigit.id
- Similar Companies
- Business
- PT Brigit Biofarmaka Teknologi Tbk is an Indonesia-based biotechnology and contract manufacturing company specializing in the research, development, formulation, and production of traditional herbal medicines, dietary supplements, functional foods, and cosmetics. Founded in 2020 and headquartered in Sukoharjo, Central Java, Indonesia, the company operates primarily as an Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM), offering end-to-end toll manufacturing services for domestic brand owners, healthcare clinics, multi-level marketing enterprises, and retail consumer brands. The company operates through three principal business segments: Herbal Medicine and Health Supplements, Cosmetics and Personal Care, and Contract Manufacturing Services. Its product portfolio includes traditional herbal remedies and dietary supplements formulated as hard capsules, liquid extracts, herbal syrups, honey blends, functional botanical teas, collagen drinks, and effervescent powders; skincare and personal care items comprising facial serums, moisturizers, sunscreens, cleansing foams, body lotions, body washes, and specialized hair care tonics; and standardized biotechnology botanical extracts. Through its integrated contract manufacturing operations, the company provides comprehensive turnkey solutions comprising formula research and development; active ingredient compounding; raw material sourcing and quality testing; regulatory registration and compliance facilitation with the Indonesian Food and Drug Authority (BPOM); Halal certification management; primary and secondary packaging design; high-volume sachet filling, blister packing, and bottling; and analytical quality assurance. In recent developments, PT Brigit Biofarmaka Teknologi Tbk completed its Initial Public Offering (IPO) on the Indonesia Stock Exchange under the ticker symbol OBAT, allocating the proceeds toward the expansion of its manufacturing capacity, laboratory upgrades, and the procurement of advanced automated packaging machinery. The company has expanded its Good Manufacturing Practices (CPOTB and CPKB) compliant facilities to increase output for liquid herbal sachets, functional wellness beverages, and dermatological skincare products. Additionally, the company established strategic supply partnerships with regional agricultural cooperatives to secure sustainable botanical raw materials such as curcuma, ginger, and moringa, while advancing its biotechnology extraction capabilities to produce standardized active compounds and accelerate commercialization timelines for corporate clients across Indonesia.